Maze Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Debjit Chattopadhyay initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $19 price target The company has advanced three small molecules into clinical development by leveraging its Compass platform, the analyst tells investors in a research note. The firm says Maze is positioned to be the second entrant in APOL1-mediated kidney disease, which it believes could morph into a $10B to $15B total addressable market. The company’s current $200M enterprise value “offers a compelling entry point for investors with a 12-month horizon,” contends Guggenheim.